Shire Looks to Protect HAE Franchise with US$5.9 B Dyax Acquisition
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2015 Issue 11 (Table of Contents)
Published: 25 Nov-2015
DOI: 10.3833/pdr.v2015.i11.2132 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
With the aim of securing its dominance in the hereditary angioedema (HAE) market through to 2030, Shire has struck a deal to buy Dyax for approximately US$5...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS